Co-Diagnostics
CODX
14 hedge funds and large institutions have $91.5K invested in Co-Diagnostics in 2026 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 18 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
2.05% more ownership
Funds ownership: 0.3% → 2.35% (+2%)
53% less funds holding
Funds holding: 30 → 14 (-16)
78% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 18
90% less capital invested
Capital invested by funds: $940K → $91.5K (-$849K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$21.6K |
| 2 |
PAG
Private Advisory Group
Redmond,
Washington
|
+$6.83K |
| 3 |
JP Morgan Chase
New York
|
+$96 |
| 4 |
Morgan Stanley
New York
|
+$51 |
| 5 |
SS
SBI Securities
Tokyo,
Japan
|
+$38 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$123K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$81.2K |
| 3 |
BlackRock
New York
|
-$72.1K |
| 4 |
Jane Street
New York
|
-$40.6K |
| 5 |
Bank of New York Mellon
New York
|
-$23.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
RIA
26
Regal Investment Advisors
Kentwood,
Michigan
| – | -$4.21K | -833 | Closed |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| – | -$2.2K | -435 | Closed |
|
|
BBA
28
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
| – | -$1.07K | -343 | Closed |
|
29
Simplex Trading
Chicago,
Illinois
| – | -$1.64K | -325 | Closed |
|
30
Bank of America
Charlotte,
North Carolina
| – | -$85 | -17 | Closed |
|
|
AIS
31
Advocate Investing Services
Woodbine,
Maryland
| – | -$13 | -3 | Closed |
|
32
BNP Paribas Financial Markets
Paris,
France
| – | -$10 | -2 | Closed |
|
CODX Hedge Fund Activity: Q1 2026 in Review
14 of the 8,134 institutional investors tracked by Wall St. Rank reported a position in Co-Diagnostics (CODX) for Q1 2026, worth a combined $91.5K — down 90% from $940K a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of CODX and 4 opened new positions — a net loss of 14 holders — while 3 trimmed existing stakes and 5 added.
The largest buyer was UBS Group, adding an estimated $21.6K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $123K sold.
- 14 institutional investors held Co-Diagnostics (CODX) as of Q1 2026, down from 30 in Q4 2025.
- Funds reported $91.5K of Co-Diagnostics stock for Q1 2026, down 90% quarter-over-quarter.
- 4 funds opened new Co-Diagnostics positions in Q1 2026 and 18 closed out, a net change of -14 holders.
- The largest Co-Diagnostics buyer in Q1 2026 was UBS Group, an estimated $21.6K added.
- The largest Co-Diagnostics seller in Q1 2026 was Renaissance Technologies, an estimated $123K sold.
Based on aggregated 13F filings for Q1 2026.